about
Peripheral mechanism of action of antimigraine prophylactic drugsActivity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Home care for brain tumor patients.The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomasPrimary headache in Emergency Department: prevalence, clinical features and therapeutical approach.Central mechanism of action of antimigraine prophylactic drugs.Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry studyTherapeutic strategies in migraine patients with mood and anxiety disorders: physiopathological basis.Polytherapy for migraine prophylaxis.Migraine and lifestyle in childhood.Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches.Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients.Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).Tapentadol in neuropathic pain cancer patients: a prospective open label study.Headache as a presenting symptom of glioma: A cross-sectional study.Palliative and Supportive Care of Patients with Intracranial Glioma.Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients.Epilepsy in the end-of-life phase in patients with high-grade gliomas.Factors affecting ¹⁸F FDOPA standardized uptake value in patients with primary brain tumors after treatment.Determinants of the severity of comorbid migraine in multiple sclerosis.Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter StudyPerampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysisPrimary headache and multiple sclerosis: preliminary results of a prospective studyZonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational studySingle-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-OncologyKyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 casesCorrection to: Phase II study of weekly carboplatin in pretreated adult malignant gliomasVastus lateralis myofascial free flap for tongue reconstruction and hypoglossal-femoral anastomosis: neurophysiological studyComorbidities in elderly patients with glioblastoma: a field-practice studyPhase II study of weekly carboplatin in pretreated adult malignant gliomasNeurocognitive evaluation in older adult patients affected by gliomaOpen Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical SeriesA multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
P50
Q28283496-00F3F346-4511-4573-8014-657F48EAA0C1Q33625227-326536CE-ECC8-4C10-A717-DA61FF9519D0Q35206222-A14D8B12-15D9-4C40-91CE-29C2CA7CEDA7Q35992345-51873A84-679E-48FA-9C01-2B9187C1214DQ36091092-4E62EC15-C6C8-46E3-A5D5-9A6762FCB751Q36260535-609F3E58-1268-4664-8232-7AB234676018Q37188680-19EB21D3-169C-4617-8F5E-5822033A4922Q37747899-87D3659C-C7C8-4779-B616-D16CBE894436Q37750575-9C3726BB-0B6B-4EC9-9828-326B0F4E6D23Q38014301-BA7AC7C4-772F-43C9-9C18-562DC0D95566Q38504741-1C6BFD74-A020-437D-9670-E342D3E5D02DQ38721455-AED71630-6D7F-4BC3-9B13-33E9495B0D1CQ38913928-96CD7B40-0C34-49D7-82E9-0E010C650648Q39596664-7890CE3A-0DC1-4E2D-BE76-B00E3955AB98Q41282384-3792E8E3-B0A3-4276-86BC-A472BBD4B6A2Q47324314-0D3A752A-56B8-4962-B184-E44EC8463423Q47375471-6B7E0375-37D8-42ED-A7DA-A20E66C21A50Q47824092-8EBEDF53-B2F4-47A4-A3AF-865B4DABF73FQ48058581-E3C71F48-E958-44C2-B256-C2C8B1DF50D8Q48327187-2D58168F-0BC3-4235-A4C9-ACD4238AA567Q48358663-8ACE1F42-5FA6-4B7C-AE82-F95A60B083A1Q48671319-FEDB2FE4-25FE-4CB5-A7E8-FFEFA170D9DDQ50317120-E8897962-B864-4335-8E50-08697D2C9E7DQ52149377-DF0EEE98-B11D-4CC9-93CC-8D8CC5C532A1Q52623784-C527F9F6-C954-4014-B8D8-40FA85B792A4Q53559851-B3538D23-B390-40BB-B87F-F7857F0C8B14Q55460980-8338CC18-6D55-49B9-BCC0-210A819596FBQ60859082-7ECF6779-B6E2-42A4-B945-77F273293B0BQ62661816-E5E242E3-1937-44E2-A126-A98E726E8FD0Q81436110-0FF68E6B-4472-405E-90E7-E1ACEC05ECA2Q83339162-BD5AB807-DF6D-4C3F-93B4-FC096FBD73A8Q88755859-2AC7B88E-FF06-4DC0-A5A9-76CD4EB69A09Q89179491-B6EA8E40-B38D-4FCD-AC93-BF66777D063FQ90009033-29AF526B-79B4-41CB-BCD3-01746525E08FQ90859383-6C4AA704-C49E-4CAC-ACD7-39AF7731DC8FQ91106430-AFDDB515-2613-4C4C-B034-948C14ED8EAEQ91624786-9F4A3CDB-4B33-407F-9F52-10AA4EF51607Q91662752-6300B5A9-5946-4C0D-8E1D-F0CEF9FFD0E3Q92879602-FAD1BE9C-21E6-40E2-9D82-755AED64FEB8Q93052157-48B484DB-5E3F-432F-B2A7-DD0B4DD5E5AD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Veronica Villani
@en
Veronica Villani
@nl
type
label
Veronica Villani
@en
Veronica Villani
@nl
prefLabel
Veronica Villani
@en
Veronica Villani
@nl
P31
P496
0000-0001-8769-9966